Journal: Alzheimer's Research & Therapy

Article Title: Peripheral administration of human recombinant ApoJ/clusterin modulates brain beta-amyloid levels in APP23 mice

doi: 10.1186/s13195-019-0498-8

Figure Lengend Snippet: Subchronic intravenous treatment of APP23 mice with human recombinant ApoJ (h-rApoJ). a Schematic timeline representing the experimental design of the study based on the subchronic administration of APP23 mice with rHDL-rApoJ nanodiscs, free rApoJ or saline. b Immunodetection (anti-h-ApoJ) of treatment samples before being intravenously infused. c Plasmatic levels of h-ApoJ in treated mice 30 min after the last administration detected by ELISA ( N = 7/group). d Levels of h-ApoJ in brain homogenates from treated mice detected by ELISA ( N = 7/group). e Immunofluorescent detection of h-ApoJ in paraffin-embedded brain sections. ** p < 0.01; *** p < 0.001

Article Snippet: To this end, after the rehydration, antigen retrieval, and blocking steps, brain slices were incubated ON with mouse-anti-human ApoJ (BD Bioscience, San Jose, CA, USA) diluted 1:100 in blocking solution.

Techniques: Recombinant, Immunodetection, Enzyme-linked Immunosorbent Assay